NewAmsterdam Pharma Co NV
NAMSHealthcare|Biotechnology|Netherlands
$35.30
-0.66 (-1.84%)
Tangible Book
$5.70
Upcoming Data Readouts (6)
Sep 2026
Est. completion
P2Antioxidant Absorption
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
NCT06982508n=100
Nov 2026
Est. completion
P3Atherosclerotic Cardiovascular Disease
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509n=9,541
Nov 2026
Est. completion
Jun 2027
Est. completion
NACardiovascular Risk
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
NCT07478887n=1,000
Nov 2027
Est. completion
P3Lipidemia
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
NCT06305559n=300
Mar 2028
Est. completion
P3Lipidemia
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602n=300
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.